Is Bafna Pharmaceuticals a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bafna Pharmaceuticals Ltd is a below average quality company .

Is Bafna Pharmaceuticals undervalued or overvalued?

The key valuation ratios of Bafna Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Bafna Pharmaceuticals share price return in the past 10 years?

Bafna Pharmaceuticals Ltd share price has appreciated 8.4% annually (CAGR) over the past ten years.

Is Bafna Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Bafna Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Bafna Pharmaceuticals?

The latest standalone P/E ratio of Bafna Pharmaceuticals as of 21-Nov-2024 is 466.13.

What is the P/B ratio of Bafna Pharmaceuticals?

The latest standalone P/B ratio of Bafna Pharmaceuticals as of 21-Nov-2024 is 2.29.

What is the 52-week high and low of Bafna Pharmaceuticals?

The 52-week high of Bafna Pharmaceuticals is Rs. 112.20 and the 52-week low is Rs. 73.35.

Bafna Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Bafna Pharmaceuticals
Brand: Bafna Pharmaceuticals

BSE: 532989 | NSE: BAFNAPH | Pharmaceuticals & Drugs | Small Cap

Place order

Bafna Pharma Share Price

₹80 -0.03 -0.04%
as on 21-Nov'24 16:59

10 Year X-Ray of Bafna Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	12.6%	-0%	-6%	-7%	-20.9%	-3%	10.6%	8.4%	16.1%	9.6%	-
Value Creation Index ⓘ	-0.1	-1.0	-1.4	-1.5	-2.5	NA	-0.2	-0.4	0.2	-0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	143	85.3	65	47.2	43.6	42.5	71.2	85.1	115	152	143
Sales YoY Gr.	-	-40.1%	-23.9%	-27.4%	-7.5%	-2.7%	67.7%	19.6%	35.5%	32.2%	-
Adj EPS ⓘ	4.4	-6.6	-10.1	-15.9	-8.3	-8.4	2.4	2.1	4.3	2.6	0.2
YoY Gr.	-	-249.8%	NA	NA	NA	NA	NA	-10.6%	102.4%	-39.1%	-
BVPS (₹) ⓘ	38.4	31.5	22	17.1	8.8	-18.6	24	26.2	31.1	34.2	35
Adj Net Profit ⓘ	8.2	-12.2	-18.8	-37.7	-19.7	-2	5.6	5	10.1	6.1	0
Cash Flow from Ops. ⓘ	9.5	-3	19.8	-7.1	-1.1	-34.3	-13.6	9.7	5	9.5	-
Debt/CF from Ops. ⓘ	6.7	-27.1	4.2	-6.6	-42.2	-0.1	-1	1.1	4.6	2.6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	0.8%	28.4%	28.9%	32.2%
Adj EPS ⓘ	-5.7%	NA	3.3%	-39.1%
BVPSⓘ	-1.3%	31.2%	12.5%	10.1%
Share Price	8.4%	76.7%	-15%	-8.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	11.6	-18.7	-35.9	-88.2	-64.4	-5.5	10.3	8.4	14.9	8	0.5
Op. Profit Mgn % ⓘ	18	3.8	-8	-74.4	-29.8	3	14.5	14	13.6	7.3	4.1
Net Profit Mgn % ⓘ	5.7	-14.4	-28.9	-80	-45.2	-4.7	7.8	5.8	8.7	4	0.3
Debt to Equity ⓘ	0.9	1.4	2	1.2	2.2	-0.7	0.2	0.2	0.3	0.3	0.1
Working Cap Days ⓘ	336	490	603	721	682	459	193	212	208	208	93
Cash Conv. Cycle ⓘ	152	247	290	236	31	3	40	74	81	79	42

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 28.88%

Return on Equity has declined versus last 3 years average to 0.50%

Sales growth is not so good in last 4 quarters at -10.10%

Latest Financials - Bafna Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	0.2	-0.9
TTM Sales (₹ Cr.)	143	42.5
BVPS (₹.) ⓘ	35	0
Reserves (₹ Cr.) ⓘ	59	-7
P/BV ⓘ	2.29	0.00
PE ⓘ	466.13	0.00

From the Market
52 Week Low / High (₹)	73.35 / 112.20
All Time Low / High (₹)	4.65 / 195.95
Market Cap (₹ Cr.)	189
Equity (₹ Cr.)	23.7
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Bafna Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Bafna Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Bafna Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	143	85	65	47	44	42	71	85	115	152
Operating Expenses ⓘ	117	83	70	82	57	41	61	73	100	141
Manufacturing Costs	14	10	8	10	11	11	14	13	14	20
Material Costs	81	62	50	33	24	16	32	40	63	87
Employee Cost	10	6	7	7	9	10	12	15	16	19
Other Costs ⓘ	12	4	6	31	13	4	4	6	7	15
Operating Profit ⓘ	25	3	-5	-35	-13	1	10	12	16	11
Operating Profit Margin (%)	17.8%	3.3%	-8.0%	-74.4%	-30.0%	2.9%	14.5%	14.0%	13.6%	7.3%
Other Income ⓘ	1	1	1	31	0	0	1	2	3	4
Interest ⓘ	12	12	11	7	2	0	1	1	2	2
Depreciation ⓘ	5	4	4	4	3	3	4	5	5	5
Exceptional Items ⓘ	-3	0	0	0	0	0	0	-2	0	0
Profit Before Tax ⓘ	6	-13	-19	-14	-18	-2	6	5	12	7
Tax ⓘ	0	0	-1	2	2	0	0	0	0	0
Profit After Tax	6	-12	-18	-16	-20	-2	6	5	11	7
PAT Margin (%)	4.3%	-14.3%	-28.4%	-34.9%	-45.2%	-4.4%	8.2%	6.1%	9.8%	4.8%
Adjusted EPS (₹)	3.3	-6.5	-9.9	-7.0	-8.3	-7.9	2.5	2.2	4.8	3.1
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	72	59	41	41	21	-4	57	62	73	81
Share Capital ⓘ	19	19	19	24	24	2	24	24	24	24
Reserves ⓘ	53	41	22	17	-3	-7	33	38	50	57
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	64	80	82	47	46	3	13	10	20	21
Long Term Debt	10	35	39	23	23	3	3	5	8	11
Short Term Debt	53	45	43	23	23	0	10	5	12	10
Trade Payables	35	30	23	28	39	13	11	12	28	35
Others Liabilities ⓘ	15	15	20	13	14	60	7	6	7	11
Total Liabilities ⓘ	185	185	167	128	121	71	86	90	130	148
Fixed Assets
Gross Block	70	72	72	73	73	74	80	88	95	99
Accumulated Depreciation	22	25	29	33	36	39	44	49	54	59
Net Fixed Assetsⓘ	49	47	43	40	37	35	36	39	40	40
CWIP ⓘ	0	0	0	0	0	0	1	0	2	12
Investmentsⓘ	18	18	18	1	1	0	0	0	0	0
Inventories	15	16	17	11	9	11	15	20	22	30
Trade Receivables	83	68	54	24	25	6	10	15	41	45
Cash Equivalents	2	3	3	3	3	8	2	0	8	1
Others Assetsⓘ	17	33	32	48	45	10	23	16	17	19
Total Assets ⓘ	185	185	167	128	121	71	86	90	130	148

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	9	-3	20	-7	-1	-34	-14	10	5	9
PBT ⓘ	6	-13	-19	-14	-18	-2	6	5	12	7
Adjustment ⓘ	-25	15	15	-20	5	-20	4	6	8	8
Changes in Working Capital ⓘ	30	-6	24	27	12	-12	-23	-1	-14	-5
Tax Paid ⓘ	-2	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	56	-1	-14	38	4	33	-5	-7	-7	-15
Capex	-8	-2	0	47	0	-1	-6	-8	-7	-15
Net Investments	15	0	0	0	0	0	0	0	0	0
Others ⓘ	49	1	-14	-9	4	34	1	1	-1	0
Cash Flow From Financing Activityⓘ	-66	4	-5	-31	-2	7	12	-5	10	-1
Net Proceeds from Shares ⓘ	-17	0	4	12	0	55	0	0	0	0
Net Proceeds from Borrowing ⓘ	-11	25	4	-16	0	-20	3	-5	12	1
Interest Paid ⓘ	-12	-12	-11	-7	-2	0	0	0	-2	-2
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-26	-8	-2	-20	0	-28	10	0	0	0
Net Cash Flow ⓘ	0	0	0	0	0	6	-7	-2	8	-6

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	9.22	-18.69	-37.05	-40.37	-64.36	N/A	22.26	8.79	16.75	9.52
ROCE (%)	12.56	-0.04	-5.98	-6.97	-20.9	N/A	10.62	8.42	16.12	9.56
Asset Turnover Ratio	0.7	0.47	0.38	0.32	0.35	0.44	0.9	0.96	1.05	1.1
PAT to CFO Conversion(x)	1.5	N/A	N/A	N/A	N/A	N/A	-2.33	2	0.45	1.29
Working Capital Days
Receivable Days	225	319	335	302	205	133	40	52	88	104
Inventory Days	53	67	91	106	83	89	69	77	67	62
Payable Days	167	191	197	280	513	586	134	106	118	134

Bafna Pharmaceuticals Ltd Stock News

Bafna Pharmaceuticals Ltd FAQs

What is the share price of Bafna Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Bafna Pharma on 21-Nov-2024 16:59 is ₹80.00.

What is the market cap of Bafna Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Bafna Pharma stood at ₹189.2.

What is the P/E ratio of Bafna Pharma?

The latest P/E ratio of Bafna Pharma as of 21-Nov-2024 16:59 is 466.1.

What is the P/B ratio of Bafna Pharma?

The latest P/B ratio of Bafna Pharma as of 21-Nov-2024 16:59 is 2.29.

What is the 52-week high and low of Bafna Pharma?

The 52-week high of Bafna Pharma is ₹112.2 and the 52-week low is ₹73.35.

What is the TTM revenue of Bafna Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bafna Pharma is ₹143.4 ( Cr.) .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals was incepted by Bafna Mahaveer Chand in 1981 as a proprietary concern. It was converted into a public limited company on 28^th march 1995. The company started its own manufacturing unit in October 1984.

Bafna Pharmaceuticals started its production with tablets facility and subsequently added capsule and oral syrup facilities respectively. BAFNA always focused on institutional and generic supply to keep its production line busy. It also concentrated on registering its products in the international market.

The present manufacturing facilities of BAFNA is set up at Chennai. The facility for producing Betalactam products was constructed in the year 2001 in a separate block.

It acquired 2.65 acres of factory land in Grantylon village, near Chennai to expand its operations to regulated market like US and UK and also to manufacture its own products.

The companyâ€™s vision is to become a leading professionally run global pharma company setting standards across the pharma value chain.

Product Range:

Antibacterials
Antipyretics
Antconvulsants
Anxiolytics
Pain management
Anthelmintics
Antifungal
Appetite stimulants
Antidiarrhoeals
Antiemetics
Hypnotics
Antacids and antiulcerants
Vitamin and dietery preparation
Cough and cold preparations
Antiasthmatics
Calcium preparations
Antihypertensives
Antidiabetics

Achievements/ Awards:

BAFNA was awarded the WHO GMP in the year 1995.
Bagged the â€˜Best Supplier Awardâ€™ from the State Pharmaceutical Corporation of Sri Lanka on 30th July 2005.
Accorded the status of an â€˜Export Houseâ€™ in recognition of its excellent export performance.
Received Medicines and Health Care Products Regulatory Agency (MHRA) approval for its Grantlyon facility meant for exports to the UK markets. Bafna was the 35th company in the Indian pharmaceuticals industry (IPI) to receive MHRA approval.
2009 ISO 9001: 2000 Certificate of Registration for Manufacture and Export of Pharmaceutical products
MHRA Certificate of GMP Compliances of Manufacturer from Medicines and Healthcare products Regulatory Agency, U.K.
2010 Bafna Pharmaceuticals have been awarded the Gold Quality Excellence Award 2009
Bafna Pharmaceuticals have inaugurated its Formulation Research & Development unit (Formulation Facility) in Chennai
2011 Bafna Pharmaceuticals has received Indian Drug Manufacturer's Association (IDMA) Quality Excellence Award 2010 - Silver Award under the category of Formulations Units
Bafna Pharmaceuticals has received Udyog Rattan Award and Excellence Award from the Institute of Economic Studies Delhi.